Contra Speaker

Date 01 October 2012
Event ESMO Congress 2012
Session EGFR inhibitors are the best choice for the first line treatment of EGFR mutated lung adenocarcinoma patients
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Presenter Benjamin Besse
Authors B. Besse
  • Dept. Of Medicine, Institute Gustave Roussy, 94805 - Villejuif/FR